OTE	 16 200	CAT SOLUTION								
				Application Nur	nber	09/938,941	file .			
ATENT	& TRADE	<b>Y</b>		Filing Date		24 August 2001 🥠				
		ION UNDER MPEP 609 I	<b>`</b>	First Named Inv	pentor	THURMOND // S				
SUBI	1122	ION UNDER MILEI 609 I	,	Group Art Unit		N/A Ko	1			
		D 1 . ( 1		Examiner Name		N/A 44				
		Page 1 of 1		Attorney Dockel	Number	ORT-1489	1 E3 V			
		U.S. PATE	NT I	DOCUMENTS			CO CO CO			
	_			U.S. Patent Doc	rument	Pages, Columns, Lines,	500			
Examiner Initials	Cite No.1	Name of Patentee or Applicant of Cited Document		Number	Kind Code² (if known)	rages, Columns, Lines, where relevant passages or relevant figures appear				
84		Palmer et al.	US	S 5,976,858						
			1.			· · · · · · · · · · · · · · · · · · ·				

7

88

11

ţ.

Examiner Signature	Dailere	B.	Oral	Date Considered	10/25/05

Germinal Center Development", Immunity (1999) 10:197-206.

Shi et al., "Cathepsin S Required for Normal MHC Class II Peptide Loading and

## DATENTT I PTED NON

Cite No.1	Name of Patentee or Applicant of Cited Document		·		Pages, Columns, Lines, where relevant passages or relevant figures appear	T⁵
	Brigham and Women's Hospital	WD	WO 99/58153			
-		No. <sup>3</sup> Applicant of Cited Document Brigham and Women's	Cite Name of Patentee or No. <sup>1</sup> Applicant of Cited Document Office <sup>3</sup> Brigham and Women's (, 17)	Cite No. <sup>1</sup> Name of Patentee or Applicant of Cited Document     Office <sup>3</sup> Number <sup>4</sup> Kin       Brigham and Women's     UVO 99/58153	No. <sup>3</sup> Applicant of Cited Document     Office <sup>3</sup> Number <sup>4</sup> KindCode <sup>3</sup> Brigham and Women's     (1, 27)     WO 99/58153     VIIII 100     VIIIII 100     VIIIII 100     VIIIII 100     VIIIII100     VIIIII 100     VI	Cite No. <sup>3</sup> Name of Patentee or Applicant of Cited Document where relevant passages of fice <sup>3</sup> where relevant passages or relevant figures appear   Brigham and Women's 6, 17 WO 99/58153 WO 99/58153

FOREIGN PATENT DOCUMENTS

		OTHER PRIOR ART - NON PATENT LITERATORE DOCOMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
81		Nakagawa et al., "Impaired Invariant Chain Degradation and Antigen Presentation and Diminished Collagen-Induced Arthritis in Cathepsin S Null Mice", Immunity (1999) 10:207-217.	
8rg		Palmer et al., "Vinyl Sulfones as Mechanism-Based Cysteine Protease Inhibitors", J. Med. Chem. (1995) 38:3193	
8ng		<u>Riese</u> et al., "Essential Role for Cathepsin S in MHC Class II-Associated Invariant Chain Processing and Peptide Loading", <i>Immunity</i> (1996) 4(4):357-366.	
81		<u>Riese</u> et al., "Cathepsin S Activity Regulates Antigen Presentation and Immunity", J. Clin. Invest. (1998) 101(11):2351-2363.	
	T		

		E.	JAN	<b>.</b> .	SDUR E				Sh	eet <u>1</u>	of1
ORM PTO-1	449		0.04	USEP ENT				ATTY. DOCKET NO.	SERIAL	NO.	
Y PATENT AND TRADEMARK OFFICE								ORT-1489	09/93	8,941	
INF	ORM/	ATI	ON	DIS	SCLC	วรเ	JRE	APPLICANT		<u> </u>	
С	ΙΤΑΤΙ							Thurmond et al.			
							y)	FILING DATE GROUP ART UNIT 24 August 2001 3763			
							ILS PAT	24 August 2001	13703		
EXAMINER		1							<u> </u>	<b>[</b>	FILING DATE
INITIAL		DO	KUN	MENT	NUMB	ER	DATE	INVENTORS	CLASS	SUBCLASS	IF APPROPRIAT
								·			
		╞╴╿	_		┥						
·		$\vdash$	+	_	$\left  - \right  -$	┢					
						I		ATENT DOCUMENTS	<u> </u>	l	
		DO	CUN	<b>NENT</b>	NUMB		DATE	COUNTRY/REGION		SUBCLASS	TRANSLATIO
				+-	┝╌┠─	_					
	<u> </u>	$\square$	╋	+	┝┼┝╌	-					
1	OTH			DCI	JMEI	NT!	S (Including	g Author, Title, Date,	Pertinent	Pages, E	tc.)
88			Con	nple				n F In Invariant Chain Pro ading By Macrophages",	, J. Exp. N	1ed., Vol. 1	91(7), pp. 11
										()~	
											,
		$ \vdash  $					<u></u>		16.	FED	VA-
		┝─┼						· · · · · · · · · · · · · · · · · · ·		57	
		┝╼┼						······································	· · · · ·	CEAL	<i>u</i> ą
										ER	Q2.
		$\square$					•				VED 104 <sup>807</sup> 00
		$\square$					<u> </u>				
							<u></u>	• •		<u> </u>	
								······································			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

- - -

. , , , ,		OT EP.(	P	E 2005	100	)					Sh	eet1_	of1	
FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT ND TRADEMARK OFFICE										rty. docket no. RT-1489	SERIAL NO. 09/938,941			
									AF	PLICANT hurmond et al.	1097950	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
CITATION BY APPLICANT (Use several sheets if necessary)									FI	LING DATE 4 August 2001	GROUP ART UNIT			
								U.S. PA		NT DOCUMENTS	- <b>4</b>			
EXAMINER INITIAL	DOCUMENT NUMBER DATE									INVENTORS	CLASS	SUBCLASS	FILING DATE	
		İΠ		Т	Τ	Τ								
					+	$\vdash$	$\square$							
										TENT DOCUMENTS	<u> </u>	l	. <u>.</u>	
		DC	CUN	AEN	TN	JMB		DATE		COUNTRY/REGION	CLASS	SUBCLASS	TRANSLATION (if applicable)	
				+	+	+				· · · · · · · · · · · · · · · · · · ·				
		$\square$		╉	┽╴	┼─		· · · · · · · · · · · · · · · · · · ·		· · · · · · · · · · · · · · · · · · ·				
	OTH	IEF		oc	:ÚN	/EN	VT.	S (Includin	ng /	Author, Title, Date, Pe	rtinen	t Pages, E	tc.)	
86			10,	pp	. 93	3-10	2 (*	1998).		ysis And MHC Class II F				
81										n Of A Potent And Se her., Vol. 308, pp. 268-27			nt Cathepsin S	
88			And	t t	he	Influ	len		His	n Of Mouse Invariant Chastocompatibility Complex				
		$\square$						· .						
			•		•			· · · ·					•	
											<u> </u>			
		$\left  \right $			-			•		<u> </u>			···· <u>····</u>	
													·····	
										· · · · · · · · · · · · · · · · · · ·				
		┝─┥						<u> </u>		•		<u></u>		
		$\square$										<u></u>		
		$\Box$											······	
		$\square$												
EXAMINER	A	   1	li			0	)	Dabil	, 0/	ATE CONSIDERED 10/25	105			
EXAMINER through ci	R: Initia	al if	cita	atio	on c	ons	side	ered, whethe	r o	r not citation is in confo dered. Include copy of th	rmance	with MPE	P 609; Draw line ommunication to	

.

applicant.

1